vs

Side-by-side financial comparison of Direct Digital Holdings, Inc. (DRCT) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.

Direct Digital Holdings, Inc. is the larger business by last-quarter revenue ($8.4M vs $5.5M, roughly 1.5× Taysha Gene Therapies, Inc.). Direct Digital Holdings, Inc. runs the higher net margin — -138.7% vs -507.8%, a 369.1% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -7.4%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -38.6%).

Devolver Digital, Inc. is an American video game publisher based in Austin, Texas, specializing in the publishing of indie games. The company was founded in June 2009 by Nigel Lowrie, Harry Miller, Graeme Struthers, Rick Stults, and Mike Wilson, five executives who had been involved with Gathering of Developers and Gamecock Media Group, which published games on developer-friendly terms, but due to the high cost associated with releasing retail games saw themselves acquired and dissolved by la...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.

DRCT vs TSHA — Head-to-Head

Bigger by revenue
DRCT
DRCT
1.5× larger
DRCT
$8.4M
$5.5M
TSHA
Growing faster (revenue YoY)
TSHA
TSHA
+178.7% gap
TSHA
171.3%
-7.4%
DRCT
Higher net margin
DRCT
DRCT
369.1% more per $
DRCT
-138.7%
-507.8%
TSHA
Faster 2-yr revenue CAGR
TSHA
TSHA
Annualised
TSHA
26.8%
-38.6%
DRCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DRCT
DRCT
TSHA
TSHA
Revenue
$8.4M
$5.5M
Net Profit
$-11.7M
$-27.9M
Gross Margin
26.8%
Operating Margin
-53.4%
-516.0%
Net Margin
-138.7%
-507.8%
Revenue YoY
-7.4%
171.3%
Net Profit YoY
-434.7%
-48.3%
EPS (diluted)
$-74.97
$-0.08

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRCT
DRCT
TSHA
TSHA
Q4 25
$8.4M
$5.5M
Q3 25
$8.0M
$0
Q2 25
$10.1M
$2.0M
Q1 25
$8.2M
$2.3M
Q4 24
$9.1M
$2.0M
Q3 24
$9.1M
$1.8M
Q2 24
$21.9M
$1.1M
Q1 24
$22.3M
$3.4M
Net Profit
DRCT
DRCT
TSHA
TSHA
Q4 25
$-11.7M
$-27.9M
Q3 25
$-2.7M
$-32.7M
Q2 25
$-2.2M
$-26.9M
Q1 25
$-2.4M
$-21.5M
Q4 24
$-2.2M
$-18.8M
Q3 24
$-2.7M
$-25.5M
Q2 24
$-590.0K
$-20.9M
Q1 24
$-775.0K
$-24.1M
Gross Margin
DRCT
DRCT
TSHA
TSHA
Q4 25
26.8%
Q3 25
27.7%
Q2 25
35.1%
Q1 25
29.3%
Q4 24
32.5%
Q3 24
38.7%
Q2 24
27.1%
Q1 24
22.4%
Operating Margin
DRCT
DRCT
TSHA
TSHA
Q4 25
-53.4%
-516.0%
Q3 25
-49.0%
Q2 25
-23.9%
-1347.1%
Q1 25
-48.1%
-930.5%
Q4 24
-51.8%
-985.8%
Q3 24
-40.3%
-1448.4%
Q2 24
-9.4%
-1915.4%
Q1 24
-12.6%
-713.3%
Net Margin
DRCT
DRCT
TSHA
TSHA
Q4 25
-138.7%
-507.8%
Q3 25
-33.6%
Q2 25
-22.2%
-1353.6%
Q1 25
-28.9%
-935.2%
Q4 24
-24.0%
-929.0%
Q3 24
-29.6%
-1427.5%
Q2 24
-2.7%
-1882.0%
Q1 24
-3.5%
-705.4%
EPS (diluted)
DRCT
DRCT
TSHA
TSHA
Q4 25
$-74.97
$-0.08
Q3 25
$-0.24
$-0.09
Q2 25
$-0.23
$-0.09
Q1 25
$-0.35
$-0.08
Q4 24
$-90.17
$-0.07
Q3 24
$-0.71
$-0.10
Q2 24
$-0.16
$-0.09
Q1 24
$-0.22
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRCT
DRCT
TSHA
TSHA
Cash + ST InvestmentsLiquidity on hand
$728.0K
$319.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-7.0M
$246.9M
Total Assets
$20.2M
$343.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRCT
DRCT
TSHA
TSHA
Q4 25
$728.0K
$319.8M
Q3 25
$871.0K
$297.3M
Q2 25
$1.6M
$312.8M
Q1 25
$1.8M
$116.6M
Q4 24
$1.4M
$139.0M
Q3 24
$4.1M
$157.7M
Q2 24
$1.1M
$172.7M
Q1 24
$3.3M
$124.0M
Total Debt
DRCT
DRCT
TSHA
TSHA
Q4 25
Q3 25
$10.8M
Q2 25
$33.5M
Q1 25
$32.9M
Q4 24
Q3 24
$150.0K
Q2 24
$34.8M
Q1 24
$32.4M
Stockholders' Equity
DRCT
DRCT
TSHA
TSHA
Q4 25
$-7.0M
$246.9M
Q3 25
$-6.7M
$219.0M
Q2 25
$-24.6M
$248.7M
Q1 25
$-23.3M
$55.1M
Q4 24
$-19.7M
$71.5M
Q3 24
$-16.7M
$88.8M
Q2 24
$-10.5M
$108.9M
Q1 24
$-7.5M
$53.8M
Total Assets
DRCT
DRCT
TSHA
TSHA
Q4 25
$20.2M
$343.3M
Q3 25
$22.5M
$316.6M
Q2 25
$23.3M
$333.3M
Q1 25
$23.8M
$138.4M
Q4 24
$26.0M
$160.4M
Q3 24
$31.3M
$180.2M
Q2 24
$48.5M
$200.4M
Q1 24
$52.8M
$153.0M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRCT
DRCT
TSHA
TSHA
Operating Cash FlowLast quarter
$-1.9M
$-26.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRCT
DRCT
TSHA
TSHA
Q4 25
$-1.9M
$-26.7M
Q3 25
$-1.6M
$-24.2M
Q2 25
$-2.7M
$-20.2M
Q1 25
$-2.7M
$-22.0M
Q4 24
$-1.6M
$-18.3M
Q3 24
$3.0M
$-21.6M
Q2 24
$-4.4M
$-21.5M
Q1 24
$-5.7M
$-19.8M
Free Cash Flow
DRCT
DRCT
TSHA
TSHA
Q4 25
Q3 25
$-24.3M
Q2 25
Q1 25
Q4 24
$-18.3M
Q3 24
$-21.6M
Q2 24
$-21.7M
Q1 24
$-19.9M
FCF Margin
DRCT
DRCT
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-905.5%
Q3 24
-1210.9%
Q2 24
-1951.9%
Q1 24
-584.5%
Capex Intensity
DRCT
DRCT
TSHA
TSHA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
2.0%
Q2 24
18.1%
Q1 24
4.1%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DRCT
DRCT

Buy Side Advertising$8.2M98%
Other$183.0K2%

TSHA
TSHA

Segment breakdown not available.

Related Comparisons